期刊文献+

MT和HDA方案治疗急性单核细胞白血病的疗效比较 被引量:3

下载PDF
导出
摘要 目的:比较MT方案(米托蒽醌联合替尼泊甙)和HDA方案(三尖杉酯碱、柔红霉素联合阿糖胞苷)治疗急性单核细胞白血病的疗效。方法:将25例急性单核细胞白血病患者随机分成2组,MT组12例、HDA组13例,分别使用以上2种方案进行化疗,比较2组的临床疗效及不良反应。结果:MT组、HDA组完全缓解率分别为92%、69%,有效率分别为92%、77%,2组差异无统计学意义,2组均出现较严重的骨髓抑制,但HDA组早于MT组发生,3例HDA方案治疗无效患者经MT方案治疗,2例达完全缓解。结论:MT方案、HDA方案治疗急性单核细胞白血病均可获得较满意的疗效,HDA方案治疗无效时可试用MT方案治疗。
出处 《临床血液学杂志》 CAS 2005年第4期235-236,共2页 Journal of Clinical Hematology
  • 相关文献

参考文献5

  • 1Zwaan C M, Kaspers G J, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood, 2000, 96:2879-2886.
  • 2Tallman M S, Kim H T, Paietta E, et al. Acute monocytic leukemia (French-American-British classification MS) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oneology Group. J Clin Oncol,2004, 22:1276-1286.
  • 3李敬兰,邓琦,李玉明,曹金霓.MA与HDA方案治疗成人急性非淋巴细胞白血病临床比较[J].中华血液学杂志,2001,22(2):103-103. 被引量:5
  • 4Muggia F M. Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother Pharmacol, 1994, 34(Suppl S1):27-33.
  • 5Haas R, Ho A D, Del Valle F, et al. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Semin Oncol, 1993, 6(Suppl 8) :20-26.

二级参考文献2

共引文献4

同被引文献17

  • 1徐雅靖,李晓林,赵谢兰,彭捷.吡柔比星与米托蒽醌治疗初治急性髓性白血病疗效对比分析[J].医学临床研究,2005,22(9):1222-1224. 被引量:2
  • 2翁春岚,潘红平.HA/DA联合维甲酸方案治疗急性单核细胞白血病26例临床观察[J].遵义医学院学报,2005,28(5):434-435. 被引量:2
  • 3章海燕.TA方案治疗急性非淋巴细胞白血病的临床疗效[J].临床和实验医学杂志,2006,5(12):1958-1959. 被引量:2
  • 4Yamada K, Shirakawa S, Ohno R, et al. A phase Ⅱ study of (2″R) -4'-0- tetrahydropyranyladriamycin (THP) in hematological malignancies. Invest New Drugs, 1987, 5: 299-305.
  • 5Tallman MS, Kim HT, Paietta E, et al. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia:a report from the Eastern Cooperative Oncology Group. J Clin Oncol, 2004, 22: 1276-1286.
  • 6Muggia FM.Teniposide:overview of its therapeutic potential in adult cancers.Cancer Chemother Pharmacol,1994,34:27-33.
  • 7Zwaan CM,Kaspers GJ,Pieters R,et al.Cellular drug resistance profiles in childhood acute myeloid leukemia:differences between FAB types and comparison with acute lymphoblastic leukemia.Blood,2000,96:2879-2886.
  • 8费霞,王法春,唐华容,江云伟,林江.伴11q23异常的急性髓系白血病的细胞遗传学分析[J].中华医学遗传学杂志,2007,24(4):485-486. 被引量:1
  • 9Zwaan CM, Kaspers GJ, Pieters R, el al. Cellular drug resistance profiles in childhood acute myeloid leukemia:differences between FAB types and comparison with acute lymphoblastic leukemia. Blood, 2000, 96:2879-2886.
  • 10Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood, 1998, 92: 2322-2333.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部